Dosing Completed in Phase 2a Trial of ANVS401

Dosing Completed in Phase 2a Trial of ANVS401

302759

Dosing Completed in Phase 2a Trial of ANVS401

Patient dosing has been completed in the Phase 2a clinical trial testing ANVS401, Annovis Bio’s investigational therapy for Alzheimer’s disease and Parkinson’s disease. An additional 40 patients with Parkinson’s disease were treated with ANVS401, with the company now preparing to share final safety and efficacy data later this year. According to a press release, Annovis Bio expects to submit all data to the U.S. Food and Drug Administration (FDA) prior to an end-of-phase meeting to determine the safety of…

You must be logged in to read/download the full post.